GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,760 ($21.83) price objective by research analysts at Deutsche Bank AG in a note issued to investors on Wednesday. The brokerage presently has a “neutral” rating on the stock. Deutsche Bank AG’s target price would indicate a potential upside of 16.71% from the stock’s previous close.

Several other analysts have also recently weighed in on the company. Jefferies Group reissued a “buy” rating and set a GBX 2,000 ($24.81) price target on shares of GlaxoSmithKline plc in a report on Thursday, August 4th. Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline plc in a report on Tuesday, August 2nd. HSBC reissued a “buy” rating and set a GBX 1,970 ($24.44) price target on shares of GlaxoSmithKline plc in a report on Monday, September 12th. Liberum Capital reissued a “buy” rating and set a GBX 1,900 ($23.57) price target on shares of GlaxoSmithKline plc in a report on Tuesday, September 13th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a GBX 1,800 ($22.33) price target on shares of GlaxoSmithKline plc in a report on Tuesday, September 20th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,729.78 ($21.46).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1513.50 on Wednesday. The stock’s 50 day moving average price is GBX 1,597.01 and its 200 day moving average price is GBX 1,588.69. GlaxoSmithKline plc has a one year low of GBX 1,277.25 and a one year high of GBX 1,745.56. The company’s market cap is GBX 73.65 billion.

The business also recently disclosed a dividend, which will be paid on Thursday, January 12th. Stockholders of record on Thursday, November 3rd will be paid a GBX 19 ($0.24) dividend. This represents a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, November 3rd.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/glaxosmithkline-plc-gsk-given-a-gbx-1760-price-target-at-deutsche-bank-ag.html.

In other news, insider Sir Andrew P. Witty sold 10,000 shares of the stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($20.30), for a total value of £163,600 ($202,952.49). Also, insider Manvinder Singh Banga acquired 1,750 shares of the stock in a transaction dated Wednesday, October 26th. The stock was bought at an average cost of GBX 1,643 ($20.38) per share, with a total value of £28,752.50 ($35,668.65).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.